alarm-ringing ambulance angle2 archive arrow-down arrow-left arrow-right arrow-up at-sign baby baby2 bag binoculars book-open book2 bookmark2 bubble calendar-check calendar-empty camera2 cart chart-growth check chevron-down chevron-left chevron-right chevron-up circle-minus circle city clapboard-play clipboard-empty clipboard-text clock clock2 cloud-download cloud-windy cloud clubs cog cross crown cube youtube diamond4 diamonds drop-crossed drop2 earth ellipsis envelope-open envelope exclamation eye-dropper eye facebook file-empty fire flag2 flare foursquare gift glasses google graph hammer-wrench heart-pulse heart home instagram joystick lamp layers lifebuoy link linkedin list lock magic-wand map-marker map medal-empty menu microscope minus moon mustache-glasses paper-plane paperclip papers pen pencil pie-chart pinterest plus-circle plus power printer pushpin question rain reading receipt recycle reminder sad shield-check smartphone smile soccer spades speed-medium spotlights star-empty star-half star store sun-glasses sun tag telephone thumbs-down thumbs-up tree tumblr twitter user users wheelchair write yelp youtube

Fenretinide May Benefit Patients With Dry AMD.

The UK’s Daily Mail (10/18, Macrae) reports that fenretinide, “a drug based on vitamin A, could prevent millions from going blind” due to dry age-related macular degeneration (AMD), according to research presented at an ophthalmology conference. In a study of nearly 250 patients with dry AMD who were randomized to fenretinide or to placebo, researchers found that “in the highest dose, the drug halted visual deterioration after a year. This suggests that while it was unable to do anything to stop cells that were already damaged from dying, it protected healthy cells.”
Bloomberg News (10/17, Olmos) reported, “The drug is believed to slow the progression of macular degeneration by reducing inflammation, inhibiting abnormal growth of blood vessels, and reducing levels of vitamin A in the retina, which can cause the formation of lesions that impair vision in people with the disease.”